Korro Bio
the OPERA (Oligonucleotide Promoted Editing of RNA) platform underpins KRRO-110 (in the REWRITE Phase 1/2a study, with FDA orphan-drug designation granted in March 2025) and the newly selected development candidate KRRO-111,…
- Country
- United States
- Ticker
- NASDAQ:KRRO
AATD editor (KRRO-110/111)
Coverage
| CN | EU | US | |
|---|---|---|---|
| therapeutics-platforms | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| RNA editing (ADAR) therapeutics | therapeutics-platforms | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.